Atom Therapeutics to Update Clinical Trials of Its Lead Drugs, a URAT1 Inhibitor for Chronic Gout and New Anti-Inflammatory Drug for Acute Gout Flares, at the BIO International Convention 2026 in San Diego

Atom Therapeutics to Update Clinical Trials of Its Lead Drugs, a URAT1 Inhibitor for Chronic Gout and New Anti-Inflammatory Drug for Acute Gout Flares, at the BIO International Convention 2026 in San Diego

Atom’s focus on chronic and acute gout aims to combat a growing worldwide gout threat with few safe and effective existing treatments for patients.

Lingdolinurad (ABP-671), a new URAT1 inhibitor, has demonstrated significant efficacy in reducing excessive serum uric acid, the cause of chronic gout; a Phase 3 trial is underway in China and two international Phase 3 trials are scheduled this year for the US.

ABP-745, a new anti-inflammatory drug, has demonstrated excellent safety and tolerability, and a Phase 2 data readout for treatment of acute gout is slated for August 2026.

Another Phase 2 trial of ABP-745 is under way for atherosclerotic cardiovascular disease (ASCVD). Studies have shown ABP-745 inhibits activation of NLRP3 inflammasome, suppresses recruitment of inflammatory cells to plaque sites, and potentially inhibits key inflammatory cytokines, thereby covering the full inflammatory cascade of atherosclerosis from endothelial injury to plaque rupture.